Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific антитело (bsAb) targeting SSTR2 связывание domain and T-клетка связывание domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC).
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC).
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.